vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and IHS Holding Ltd (IHS). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $254.0M, roughly 1.1× IHS Holding Ltd). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.1%). IHS Holding Ltd produced more free cash flow last quarter ($178.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -22.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world, with operations across Africa and Latin America. It is the fifth-largest independent multinational tower company in the world.
GH vs IHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $254.0M |
| Net Profit | $-128.5M | — |
| Gross Margin | 64.6% | 83.6% |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | — |
| Revenue YoY | 39.4% | 0.1% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $254.0M | ||
| Q3 25 | $265.2M | $455.1M | ||
| Q2 25 | $232.1M | $433.3M | ||
| Q1 25 | $203.5M | $439.6M | ||
| Q4 24 | $201.8M | $253.8M | ||
| Q3 24 | $191.5M | $420.3M | ||
| Q2 24 | $177.2M | $435.4M | ||
| Q1 24 | $168.5M | $417.7M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $147.4M | ||
| Q2 25 | $-99.9M | $32.3M | ||
| Q1 25 | $-95.2M | $30.7M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $-205.7M | ||
| Q2 24 | $-102.6M | $-124.3M | ||
| Q1 24 | $-115.0M | $-1.6B |
| Q4 25 | 64.6% | 83.6% | ||
| Q3 25 | 64.7% | 47.5% | ||
| Q2 25 | 65.0% | 51.3% | ||
| Q1 25 | 63.3% | 51.4% | ||
| Q4 24 | 61.6% | 72.1% | ||
| Q3 24 | 61.1% | 52.0% | ||
| Q2 24 | 59.1% | 52.5% | ||
| Q1 24 | 61.2% | 39.1% |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | 35.1% | ||
| Q2 25 | -45.9% | 33.8% | ||
| Q1 25 | -54.6% | 37.1% | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | 29.9% | ||
| Q2 24 | -56.8% | 34.0% | ||
| Q1 24 | -59.2% | -1.7% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | 32.4% | ||
| Q2 25 | -43.0% | 7.5% | ||
| Q1 25 | -46.8% | 7.0% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | -48.9% | ||
| Q2 24 | -57.9% | -28.5% | ||
| Q1 24 | -68.2% | -372.8% |
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | $0.44 | ||
| Q2 25 | $-0.80 | $0.10 | ||
| Q1 25 | $-0.77 | $0.10 | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | $-0.61 | ||
| Q2 24 | $-0.84 | $-0.36 | ||
| Q1 24 | $-0.94 | $-4.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $825.7M |
| Total DebtLower is stronger | $1.5B | $3.1B |
| Stockholders' EquityBook value | $-99.3M | $-89.8M |
| Total Assets | $2.0B | $4.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $825.7M | ||
| Q3 25 | $580.0M | $647.6M | ||
| Q2 25 | $629.1M | $531.8M | ||
| Q1 25 | $698.6M | $629.0M | ||
| Q4 24 | $525.5M | $578.0M | ||
| Q3 24 | $585.0M | $397.5M | ||
| Q2 24 | $933.7M | $445.7M | ||
| Q1 24 | $1.0B | $333.2M |
| Q4 25 | $1.5B | $3.1B | ||
| Q3 25 | $1.1B | $3.3B | ||
| Q2 25 | $1.1B | $3.2B | ||
| Q1 25 | $1.1B | $3.4B | ||
| Q4 24 | $1.1B | $3.3B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $3.5B |
| Q4 25 | $-99.3M | $-89.8M | ||
| Q3 25 | $-354.5M | $38.1M | ||
| Q2 25 | $-305.5M | $-98.4M | ||
| Q1 25 | $-250.8M | $-184.4M | ||
| Q4 24 | $-139.6M | $-314.4M | ||
| Q3 24 | $-60.1M | $-284.7M | ||
| Q2 24 | $-1.6M | $-308.3M | ||
| Q1 24 | $68.3M | $-163.2M |
| Q4 25 | $2.0B | $4.5B | ||
| Q3 25 | $1.3B | $4.7B | ||
| Q2 25 | $1.3B | $4.5B | ||
| Q1 25 | $1.3B | $4.4B | ||
| Q4 24 | $1.5B | $4.2B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.6B | $4.5B | ||
| Q1 24 | $1.7B | $4.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | 85.85× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $246.9M |
| Free Cash FlowOCF − Capex | $-54.2M | $178.6M |
| FCF MarginFCF / Revenue | -19.3% | 70.3% |
| Capex IntensityCapex / Revenue | 9.9% | 26.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $718.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $246.9M | ||
| Q3 25 | $-35.4M | $251.3M | ||
| Q2 25 | $-60.3M | $237.7M | ||
| Q1 25 | $-62.7M | $200.3M | ||
| Q4 24 | $-64.5M | $344.4M | ||
| Q3 24 | $-51.1M | $174.5M | ||
| Q2 24 | $-94.0M | $134.7M | ||
| Q1 24 | $-30.3M | $75.8M |
| Q4 25 | $-54.2M | $178.6M | ||
| Q3 25 | $-45.8M | $189.2M | ||
| Q2 25 | $-65.9M | $197.7M | ||
| Q1 25 | $-67.1M | $153.2M | ||
| Q4 24 | $-83.4M | $282.9M | ||
| Q3 24 | $-55.3M | $122.3M | ||
| Q2 24 | $-99.1M | $74.2M | ||
| Q1 24 | $-37.2M | $14.8M |
| Q4 25 | -19.3% | 70.3% | ||
| Q3 25 | -17.3% | 41.6% | ||
| Q2 25 | -28.4% | 45.6% | ||
| Q1 25 | -33.0% | 34.8% | ||
| Q4 24 | -41.3% | 111.5% | ||
| Q3 24 | -28.9% | 29.1% | ||
| Q2 24 | -55.9% | 17.0% | ||
| Q1 24 | -22.1% | 3.5% |
| Q4 25 | 9.9% | 26.9% | ||
| Q3 25 | 3.9% | 13.6% | ||
| Q2 25 | 2.4% | 9.2% | ||
| Q1 25 | 2.2% | 10.7% | ||
| Q4 24 | 9.4% | 24.2% | ||
| Q3 24 | 2.2% | 12.4% | ||
| Q2 24 | 2.9% | 13.9% | ||
| Q1 24 | 4.1% | 14.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 7.36× | ||
| Q1 25 | — | 6.52× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IHS
Segment breakdown not available.
